Communiqués Scholar Rock Holding Corporation

Actions

SRRK

US80706P1030

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/08/2026			Varia. 5j.	Varia. 1 janv.
52,07 ^USD	+0,35%		+13,57%	+18,21%

10/08	Scholar Rock Holding confirme que l'examen de la BLA pour l'apitegromab reste en bonne voie pour la date PDUFA du 30 septembre	MT
10/08	Novo Nordisk répond aux observations de la FDA concernant son usine de l'Indiana	FW

Communiqués

07/08	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date	BU
06/08	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights	BU
29/07	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference	BU
20/07	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)	BU
17/07	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
16/07	Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026	BU
22/06	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD	BU
12/06	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
26/05	Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	BU
20/05	Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference	BU
15/05	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
07/05	Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights	BU
29/04	Scholar Rock to Present at the BofA Securities 2026 Health Care Conference	BU
20/04	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
17/04	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
16/04	Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026	BU
31/03	Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)	BU
13/03	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
03/03	CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights	BU
18/02	Scholar Rock to Present at Upcoming Investor Conferences	BU
13/02	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/02	Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026	BU
19/01	Scholar Rock Reports New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
16/01	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
12/01	Scholar Rock : SRRK Investor Presentation JPM 11Jan2025 FINAL SUBMITTED	PU